Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric cenobamate study in focal seizures
2023-506841-52-00Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in epilepsy, sponsored by SK Life Science, Inc. Primary endpoint: Treatment-emergent adverse events and serious adverse events during first year. Started Mar 2023; status: completed.
02
Drugs
cenobamate
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2023-506841-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506841-52-00.